SOPH Chief Medical Officer Philippe Menu Sells $25K of Stock

Chief Medical Officer Philippe Menu sold 5,000 shares of SOPHiA GENETICS SA (NASDAQ: SOPH) on June 12, 2026. According to the regulatory filing, the transaction was completed at an average price of $4.95 per share, representing a total value of $24,750. This transaction was executed under a pre-arranged trading plan, which allows company insiders to schedule trades ahead of time.

Details of Philippe Menu's Planned Sale

This transaction was a scheduled trade that took place in early summer. The sale of 5,000 shares represents a minor adjustment to Menu's holdings. The transaction is part of a broader pattern of executive trades at the Switzerland-based company during the same period, with several other high-level managers adjusting their positions in June.

SOPHiA GENETICS Stock Performance and Key Levels

On Tuesday, shares of SOPHiA GENETICS closed at $5.01. The stock has been trading within a 52-week range of $3.37 to $8.98. Looking at its trendlines, the stock is currently trading below its 50-day moving average of $7.28 and its 200-day moving average of $5.55. The company maintains a current ratio of 2.688 and a quick ratio of 2.384, with a debt-to-equity ratio of 74.385.

Recent Earnings and Financial Metrics

In its financial reports, SOPHiA GENETICS reported total revenue of $86,167,000, showing a revenue growth rate of 0.272. The company is still working toward profitability, posting an earnings per share of -1.16, a negative net margin of -0.93862, and a negative return on equity of -1.01218. Because the firm does not have positive net income, it has no meaningful price-to-earnings ratio, though its forward P/E ratio is -16.48. Shareholders are looking forward to the next earnings announcement on November 3, 2026.

A Busy Summer of Insider Trading at SOPHiA GENETICS

Menu's June 12 transaction was followed by several other executive moves later in the month. On June 25, 2026, Menu executed another planned sale of 5,000 shares at $5.50, totaling $27,500. On that same day, Chief Technology Officer Abhimanyu Verma sold 6,944 shares at an average price of $5.51, totaling $38,261.44. Chief Executive Officer Jurgi Camblong was also highly active. Camblong completed a planned sale of 1,373 shares on June 25, 2026, at $5.70 per share, totaling $7,826.10. The next day, on June 26, 2026, the CEO exercised options to buy 31,940 shares at $3.16 per share, valued at $100,930.40, while also reporting a separate transaction involving 31,940 shares with no listed price.

What Wall Street Analysts Say About SOPH

Despite the recent executive sales, institutional analysts have kept a highly positive outlook on the stock. On October 12, 2026, HC Wainwright & Co. reiterated its buy rating on SOPH, keeping its price target at $14.0. This followed an August 5, 2026 update where the same firm maintained its buy rating and raised its target to $14.0 from $12.0. On that same day in August, BTIG maintained its buy rating, lifting its target to $9.0 from $8.0. Earlier, on July 20, 2026, HC Wainwright & Co. initiated coverage on the stock with a buy rating and a $12.0 target. Overall, the four analysts covering the stock have a mean target price of $9.75, with estimates ranging from a low of $7.0 to a high of $14.0.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology firm headquartered in Rolle, Switzerland. The company operates a cloud-based software platform, SOPHiA DDM, which helps hospitals and clinical laboratories analyze genomic and other complex medical datasets to support precision medicine.

What to Watch at SOPHiA GENETICS SA

Market participants will be watching the upcoming earnings release on November 3, 2026, to see if the company's strong revenue growth is translating into narrower losses. While insider transactions can offer a look into how executives manage their personal stakes, planned trades are arranged months in advance and do not necessarily signal a change in business fundamentals.